StockNews.AI
ZEAL
StockNews.AI
103 days

Zealand Pharma announces closing of collaboration and license agreement with Roche

1. Zealand Pharma finalized a collaboration with Roche on March 12, 2025. 2. The partnership aims to enhance obesity management via petrelintide. 3. Zealand has over 10 drug candidates in clinical development. 4. The collaboration may unlock commercial potential for Zealand's products. 5. CEO expresses optimism about the future of obesity treatment.

4m saved
Insight
Article

FAQ

Why Bullish?

The collaboration with Roche indicates strong potential for product development. Similar partnerships historically boost biotech stock values, as seen with smaller firms gaining market presence.

How important is it?

The collaboration enhances ZEAL's market position and could lead to revenue growth, appealing to investors.

Why Long Term?

The partnership will take time to drive revenue but sets a foundation for future growth.

Related Companies

RHHBYAMGNBIIB
May 09, 2025 00:25 ET  | Source: Zealand Pharma Company announcement – No. 12 / 2025 Zealand Pharma announces closing of collaboration and license agreement with Roche Copenhagen, Denmark, May 9, 2025 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces that all closing conditions in the collaboration and license agreement with Roche announced on March 12, 2025 have been satisfied, including regulatory conditions, and the agreement has become effective. “We are incredibly excited to launch this partnership, which represents a step change to realize Zealand Pharma’s vision of becoming a key player in the future management of obesity. Roche ticked all the right boxes for what we were looking for in a partner and we look very much forward to working closely together to unlock the full potential of petrelintide to benefit people who are overweight or obese”, said Adam Steensberg, Chief Executive Officer at Zealand Pharma.  # # # About Zealand Pharma A/SZealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with a number of pharma companies as well as commercial partnerships for its marketed products. Zealand was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the United States. For more information about Zealand’s business and activities, please visit www.zealandpharma.com. ContactsAdam Lange (Investors)Vice President, Investor Relations Zealand PharmaEmail: alange@zealandpharma.com Neshat Ahmadi (Investors)Investor Relations ManagerZealand PharmaEmail: neahmadi@zealandpharma.com Anna Krassowska, PhD (Investors and Media) Vice President, Investor Relations & Corporate Communications Zealand Pharma Email: akrassowska@zealandpharma.com

Related News